Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Yao

Showing results (231-240 of 253) with videos related to

Pageof 26
Sort By:
Gene Therapy|November 4, 2005
Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2C-J Yu, L-T Jia, Y-L Meng, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonistsGregory A Gfesser, Henry Zhang, Jurgen Dinges, et al.
Journal of Medicinal Chemistry|November 20, 2009
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activityJennifer M Frost, Michael J Dart, Karin R Tietje, et al.
Journal of Neuroscience Methods|July 5, 2011
KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channelsDi Zhang, Rama Thimmapaya, Xu-Feng Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 15, 2014
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysisK Kubota, Y Ichinose, G Scagliotti, et al.
European Journal of Pharmacology|March 23, 2004
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonistArthur A Hancock, Youssef L Bennani, Eugene N Bush, et al.
Zhonghua Yi Xue Za Zhi|December 13, 2018
[Glycemic control and its associated factors in children and adolescents with type 1 diabetes mellitus]P Ling, Y Zhang, S H Luo, et al.
Biochemical Pharmacology|August 6, 2004
Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonistTimothy A Esbenshade, Gerard B Fox, Kathleen M Krueger, et al.
Journal of Medicinal Chemistry|March 4, 2008
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activityJennifer M Frost, Michael J Dart, Karin R Tietje, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like propertiesTimothy A Esbenshade, Gerard B Fox, Kathleen M Krueger, et al.
Pageof 26

Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
Gene Therapy|November 4, 2005
Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2C-J Yu, L-T Jia, Y-L Meng, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonistsGregory A Gfesser, Henry Zhang, Jurgen Dinges, et al.
Journal of Medicinal Chemistry|November 20, 2009
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activityJennifer M Frost, Michael J Dart, Karin R Tietje, et al.
Journal of Neuroscience Methods|July 5, 2011
KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channelsDi Zhang, Rama Thimmapaya, Xu-Feng Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 15, 2014
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysisK Kubota, Y Ichinose, G Scagliotti, et al.
European Journal of Pharmacology|March 23, 2004
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonistArthur A Hancock, Youssef L Bennani, Eugene N Bush, et al.
Zhonghua Yi Xue Za Zhi|December 13, 2018
[Glycemic control and its associated factors in children and adolescents with type 1 diabetes mellitus]P Ling, Y Zhang, S H Luo, et al.
Biochemical Pharmacology|August 6, 2004
Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonistTimothy A Esbenshade, Gerard B Fox, Kathleen M Krueger, et al.
Journal of Medicinal Chemistry|March 4, 2008
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activityJennifer M Frost, Michael J Dart, Karin R Tietje, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like propertiesTimothy A Esbenshade, Gerard B Fox, Kathleen M Krueger, et al.
Pageof 26